• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Merck continues plans to cut jobs

Merck continues plans to cut jobs

July 15, 2011
CenterWatch Staff

Last year, Merck disclosed plans to save up to $3.5 billion by closing numerous research sites and manufacturing plants and eliminate roughly 15,000 jobs by 2012, or roughly 10% of the total headcount including the thousands of employees who were part of the 2009 acquisition of Schering-Plough. Before that deal, Merck employed about 53,000 people, reported Pharmalot.

By March, Merck had managed to get headcount down to 93,000, which means another 8,000 or so jobs must still go. Sources say the layoff process is expected to accelerate in early August, as the drug maker continues its restructuring plan and looks for additional ways to save money.

That more pink slips will be handed out is hardly surprising, given that Merck telegraphed the cuts a year ago. Numerous departments have been winnowed in recent months, particularly the Merck Research Laboratories, which once led the industry in new discoveries but now struggles to replenish the pipeline.

Merck execs are interested in bringing the headcount down further, sources say, and are continuing to review more operations, including reducing the scale of the research facility that opened in Boston seven years ago. A Merck spokesman, however, declined to comment on any upcoming moves.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing